WHO Pilot Procedure for Prequalification of Rituximab / Trastuzumab

05 July 2018: WHO launched a pilot project for prequalifying biotherapeutic medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries. To that end, WHO is inviting manufacturers to submit applications for prequalification of two biotherapeutic products: Rituximab (used principally to treat non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia), and Trastuzumab (used to treat breast cancer) and their corresponding similar biotherapeutic products. For more information: http://www.who.int/medicines/regulation/biotherapeutic_products/en/